Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Is BioMarin Pharmaceuticals Stock a Buy?

TheMotleyFool

0 0

Is BioMarin Pharmaceuticals Stock a Buy?Photo, wide shot, wide-angle lens, Clinical research organization, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by David Maisel: https://img.theapi.app/temp/0e9d087d-988e-4397-b7cf-6049e2776769.png

BioMarin Pharmaceuticals (NASDAQ: BMRN) has not escaped the market sell-off caused by the COVID-19 pandemic. The stock dropped 21% from its high of $97.10, set March 4, before quickly rebounding; year to date, the biopharma's shares are down 5%. BioMarin is trading at 59.2 times future earnings, and the company's forward price-to-earnings-growth (PEG) ratio is 0.76. Given these valuation metrics, should investors consider buying shares?

BioMarin has a broad portfolio of commercialized drugs targeting rare genetic disorders. Marketed globally in more than 75 countries, these drugs offer steady revenue growth.

Image source: Getty Images.

Source Fool.com

Like: 0

BMRN

Teilen